Our Bond, Inc. R&D increased by 24.5% to $691.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.5%, from $555.00K to $691.00K.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $678.25K | $678.25K | $678.25K | $678.25K | $555.00K | $691.00K |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -18.2% | +24.5% |
| YoY Change | — | — | — | — | -18.2% | +24.5% |